Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

07741

Supelco

Everolimus

analytical standard

Sinonimo/i:

CERTICAN®, 42-O-(2-Hydroxyethyl)rapamycin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C53H83NO14
Numero CAS:
159351-69-6
Peso molecolare:
958.22
Numero MDL:
MFCD00929329
Codice UNSPSC:
41116107
ID PubChem:
329748511

Grado

analytical standard

Saggio

≥95% (HPLC)

Durata

limited shelf life, expiry date on the label

tecniche

HPLC: suitable
gas chromatography (GC): suitable

applicazioni

forensics and toxicology
pharmaceutical (small molecule)
veterinary

Temperatura di conservazione

−20°C

Stringa SMILE

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
HKVAMNSJSFKALM-GKUWKFKPSA-N

Informazioni sul gene

human ... FKBP1A(2280)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Confezionamento

Bottomless glass bottle. Contents are inside inserted fused cone.

Risultati analitici

Exact concentration and expiry date can be found on the certificate, included in each package.

Note legali

CERTICAN is a registered trademark of Novartis AG

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Health hazardEnvironment
GHS08,GHS09

Avvertenze

Warning

Indicazioni di pericolo

H351,H361fd,H373,H410

Classi di pericolo

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

Organi bersaglio

Kidney,Testes

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number
BCBS2040V
BCBR8517V
BCBP8733V
BCBP1603V
BCBM2224V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Inge Verbrugge et al.
Radiation research, 182(2), 219-229 (2014-06-25)
Radiotherapy is a successful treatment modality for localized cancer. Our group has been exploring radiotherapy in combination with immunotherapy (radioimmunotherapy) to enhance systemic antitumor responses. Previously, we have shown that when local radiotherapy was combined with monoclonal antibodies (mAbs) (that
Robert J Motzer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(25), 2765-2772 (2014-07-23)
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma. RECORD-3 used a crossover treatment
Atsushi Ohtsu et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3935-3943 (2013-09-18)
The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in
Simron Singh et al.
Neuroendocrinology, 106(3), 211-220 (2017-05-30)
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine
Joëlle Elias et al.
Heart (British Cardiac Society), 104(17), 1432-1438 (2018-02-22)
During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.